Cogent Biosciences receives moderate buy rating from analysts

Cogent Biosciences, Inc. has received an average recommendation of ‘Moderate Buy’ from thirteen analysts covering the stock. The ratings breakdown includes eight buy ratings, two strong buy ratings, two hold ratings, and one sell rating.

Recent analyst activity includes Wedbush restating an ‘outperform’ rating with a $55.00 price target, and HC Wainwright boosting its price objective to $55.00 with a ‘buy’ rating. Conversely, Weiss Ratings reissued a ‘sell (d-)’ rating in July. The company’s market capitalization is approximately $6.61 billion. In its most recent quarterly earnings report, Cogent Biosciences reported earnings per share of ($0.52), which exceeded the consensus estimate of ($0.55).